What is the fair value of Ultragenyx (NASDAQ-RARE) stock?

The current fair value estimate for Ultragenyx (NASDAQ-RARE) is $18.79. This implies an estimated upside of 20.3% versus the current market price.

Is Ultragenyx (NASDAQ-RARE) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 20.3% versus the current market price.

What is the analyst price target for NASDAQ-RARE stock?

The available analyst price target for Ultragenyx (NASDAQ-RARE) is $28.05. The analyst target implies estimated upside of 79.6%.

How is the financial health of Ultragenyx?

The current financial health read for Ultragenyx (NASDAQ-RARE) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Ultragenyx's next earnings date?

The next earnings date currently listed for Ultragenyx (NASDAQ-RARE) is November 4, 2026.

Does Ultragenyx (NASDAQ-RARE) pay dividends?

The latest available data indicates no current dividend yield for Ultragenyx (NASDAQ-RARE).

What is the market capitalization of Ultragenyx?

The current market capitalization listed for Ultragenyx is 1.535 B.

What is the enterprise value of Ultragenyx?

The current enterprise value listed for Ultragenyx is 2.308 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Ultragenyx?

The ticker symbol for Ultragenyx is NASDAQ-RARE, and the stock is listed on NASDAQ.

Where is Ultragenyx (NASDAQ-RARE) listed?

Ultragenyx (NASDAQ-RARE) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Ultragenyx?

The current debt-to-total-capital ratio listed for Ultragenyx is 45.2%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Ultragenyx?

The free float listed for Ultragenyx is 81.8%. Free float helps investors understand how much of the share base is available for public trading.

Ultragenyx (RARE) Fair Value & Stock Analysis

Ultragenyx (RARE)

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing therapies for rare and ultra-rare genetic diseases. The company’s commercial portfolio includes Crysvita (burosumab), used for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza for homozygous familial hypercholesterolemia. Its development pipeline includes multiple late-stage programs such as UX143, UX111, DTX401, DTX301, and GTX-102, along with earlier-stage candidates like UX701 and UX053. Ultragenyx collaborates with several academic institutions and biopharmaceutical partners across its research programs. Founded in 2010 and headquartered in Novato, California, the company operates across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-RARE	$18.79	20.3% Upside	Undervalued	$28.05	79.6% Upside	Bargain	Fair	0.0%	November 4, 2026	2.1x	1.535 B	2.308 B	45.2%	81.8%	-6.5	83.4%